Home Biosimilar Antibodies Immunology & Inflammation CD markers Favezelimab (Anti-LAG3 / CD223)
For research use only. Not for use in humans.

Favezelimab (Anti-LAG3 / CD223)

Synonyms: LAG-3， CD223

Favezelimab (Anti-LAG3 / CD223) is a humanized monoclonal antibody that targets LAG-3. It has the potential for colorectal cancer (CRC) research. MW :145.98 KD.

Favezelimab (Anti-LAG3 / CD223)

Quality Control

  • Cited in Nature Medicine for its top-tier quality
  • SDS
  • Datasheet
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Favezelimab (Anti-LAG3 / CD223) is a humanized monoclonal antibody that targets LAG-3. It has the potential for colorectal cancer (CRC) research. MW :145.98 KD.
References

Product Details

CAS No. 2231068-83-8
Molecular Weight 145.98
Isotype Human IgG4SP
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07567469 NOT_YET_RECRUITING Drug: Cemiplimab|Drug: Cemiplimab+Fianlimab Fixed Dose Combi High-Grade Glioma (HGG); Posterior Fossa-A Ependymoma Regeneron Pharmaceuticals 2026-08-31 PHASE1; PHASE2
NCT05800015 ACTIVE_NOT_RECRUITING Drug: fianlimab|Drug: cemiplimab|Drug: Pemetrexed|Drug: Pacl Non-small Cell Lung Cancer Regeneron Pharmaceuticals 2023-08-08 PHASE2; PHASE3
NCT04938817 ACTIVE_NOT_RECRUITING Drug: lenvatinib Small Cell Lung Carcinoma Merck Sharp & Dohme LLC 2021-08-19 PHASE1; PHASE2
NCT06395090 WITHDRAWN Neoplasm Metastasis Merck Sharp & Dohme LLC 2025-01-15 PHASE1; PHASE2
NCT06571708 RECRUITING Drug: Gemcitabine|Drug: Cisplatin|Drug: Cemiplimab|Drug: Fia Bladder Cancer; Muscle-Invasive Bladder Carcinoma Columbia University 2025-08-14 PHASE2
NCT06325683 SUSPENDED Drug: Lomustine Progressive Glioblastoma; Recurrent Glioblastoma National Cancer Institute (NCI) 2024-11-08 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-05-05)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.